Tecfidera
Manufacturing · North Carolina, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
5000 Davis Dr, Durham, North Carolina, 2...Website
www.tecfidera.comRevenue
$5.7 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Tecfidera
Biogen offers Tecfidera® (dimethyl fumarate), a prescription medication designed for the treatment of relapsing forms of multiple sclerosis (MS) in adults. The product is aimed at individuals diagnosed with clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. Biogen provides comprehensive information on the efficacy, safety, and management of potential side effects associated with Tecfidera. The company also supports healthcare providers and patients with resources and tools for managing MS treatment.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Tecfidera your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Tecfidera, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Tecfidera has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Tecfidera has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Tecfidera recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Tecfidera
Check out if Tecfidera is spiking on competitors!
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Tecfidera launches new products
Click to see if Tecfidera had a recent Job posting/layoffs
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Tecfidera
Compare insights from companies similar to Tecfidera, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Company Profile Activity
Activity Insights
Tecfidera is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Tecfidera is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Tecfidera.
Tecfidera Tech Stack
A closer look at the technologies used by Tecfidera
Tecfidera News & Media
Genentech's Ocrevus Offers Stiff Competition to the New High-Efficacy Oral Therapies, Novartis' Mayzent and EMD Serono's Mavenclad, While Biogen's Vumerity Begins to Chip Away at the Company's Own Tecfidera
EXTON, Pa., March 10, 2020 /PRNewswire/ -- In the last year, the US multiple sclerosis (MS) market saw the introduction of three new disease-modifying therapies (DMTs) for the treatment of relapsing forms of MS (RMS). Fielded between January 21 and February 12, data from 100 neurologists...Banner Life Sciences Announces First Subject Enrolled in Randomized, Double-Blind Head-to-Head Study of BAFIERTAM and Tecfidera for Comparative Assessment of GI Tolerability
HIGH POINT, N.C.--(BUSINESS WIRE)--Banner announces first subject has been enrolled in a head-to-head study of BAFIERTAM and Tecfidera for comparative assessment of GI tolerability.Banner Receives FDA Tentative Approval for BAFIERTAM for the Treatment of Relapsing Forms of Multiple Sclerosis
HIGH POINT, N.C.--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/FDA?src=hash" target="_blank"gt;#FDAlt;/agt;--Banner Receives FDA Tentative Approval for BAFIERTAM for the Treatment of Relapsing Forms of Multiple SclerosisForward Pharma Provides Update on the Decision of the Federal Circuit in its Appeal of the U.S. Patent Interference
COPENHAGEN, Denmark, Oct. 24, 2018 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ: FWP) (“Forward” or the “Company”) today announced that the U.S. Court of Appeals for the Federal Circuit (the “Federal Circuit”) has affirmed the decision of the Patent Trial and Appeal Board (the “PTAB”) in the interference proceeding (the “Interference”) between Forward’s U.S. Patent Application No. 11/576,871 (the “’871 application”) and an issued Biogen patent.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Tecfidera
Sign Up For FreeTo access detailed company insights
Biogen offers Tecfidera® (dimethyl fumarate), a prescription medication designed for the treatment of relapsing forms of multiple sclerosis (MS) in adults. The product is aimed at individuals diagnosed with clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. Biogen provides comprehensive information... Read More
